Saturday, 17 October 2026European Markets

ZENOBE GRAMME CERT Stock 12.64% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with ZENOBE GRAMME CERT (ZEN.BR) rising 12.64% to €196.00 on Monday while BEL 20 rose 0.1% to €3,707.77.

ZENOBE GRAMME CERT's last close was €196.00, 12.46% below its 52-week high of €223.90.

About ZENOBE GRAMME CERT

Immo-Zenobe Gramme SA engages in the issuance of real estate certificates in Belgium. Immo-Zenobe Gramme SA is based in Molenbeek-Saint-Jean, Belgium. Immo-Zenobe Gramme SA operates as a subsidiary of KBC Bank NV.

Earnings Per Share

As for profitability, ZENOBE GRAMME CERT has a trailing twelve months EPS of €0.17.

PE Ratio

ZENOBE GRAMME CERT has a trailing twelve months price to earnings ratio of 1152.94. Meaning, the purchaser of the share is investing €1152.94 for every euro of annual earnings.

Volatility

ZENOBE GRAMME CERT's last week, last month's, and last quarter's current intraday variation average was 5.46%, 2.23%, and 5.40%.

ZENOBE GRAMME CERT's highest amplitude of average volatility was 7.18% (last week), 3.54% (last month), and 5.40% (last quarter).

Volume

Today's last reported volume for ZENOBE GRAMME CERT is 27 which is 18.18% below its average volume of 33.

More news about ZENOBE GRAMME CERT (ZEN.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com